Shares of Lear Corporation LEA scaled a 52-week high of $ 192.13 on Jan 5, eventually closing at $ 191.39.
Lear Corporation has a market cap of roughly $12.9 billion. Average volume of shares traded is around 459,243. The company has an expected long-term EPS growth of 7.1%.
The stock has seen the Zacks Consensus Estimate for fiscal 2018 being revised 0.4% upward, respectively, over the last 30 days. The company delivered a positive earnings surprise in each of the trailing four quarters, the average beat being 7.5%.
Shares of Lear Corporation have gained 10.1% in the past three months, outperforming the industry 's 5.4% growth.
Lear Corporation is a top supplier of automotive seating systems, electrical distribution systems and electronics. Recently, the company inked a deal for acquiring Israel-based EXO Technologies, which is engaged in developing innovative software-based solutions for GPS. The acquisition is likely to provide Lear with a different technology to appreciably enhance GPS accuracy and reliability. This will in turn improve vehicle safety and assist in autonomous driving.
Last year, Lear Corporation announced the inking of a new credit agreement. This move was aimed at enhancing the financial flexibility of the company and positioning it well, in order to take advantage of the conducive market conditions.
Lear Corporation currently has a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 (Strong Buy) Rank stocks here .
Allison Transmission has a long-term growth rate of 10%. The company's shares have gained 35.6% in the past 12 months.
Denso has a long-term growth rate of 10.1%. The company's shares have gained 23.5% in the past 12 months.
Oshkosh has a long-term growth rate of 16.5%. The company's shares have gained 35.7% in the past 12 months.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.